三星医疗(601567) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 reached ¥3,024,788,914.34, representing a year-on-year increase of 34.53%[4] - The net profit attributable to shareholders for Q1 2024 was ¥364,254,826.35, reflecting a growth of 35.15% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥375,247,740.28, which is an increase of 41.24% year-on-year[4] - Basic earnings per share for Q1 2024 were ¥0.26, up 35.85% from the previous year[4] - Diluted earnings per share also stood at ¥0.26, reflecting a 35.85% increase year-on-year[4] - The weighted average return on equity was 3.26%, an increase of 0.47 percentage points compared to the previous year[4] - The total comprehensive income for the period was CNY 364,574,945.30, up from CNY 286,068,051.13 in the previous year, marking an increase of about 27.5%[20] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 59.69% to ¥99,347,382.01, primarily due to increased material procurement and expense outlays[4] - The net cash flow from operating activities for Q1 2024 was CNY 99,347,382.01, a decrease from CNY 246,430,917.01 in Q1 2023, indicating a decline of about 59.8%[22] - The company reported a net cash outflow from investing activities of CNY -157,191,155.75 in Q1 2024, contrasting with a net inflow of CNY 19,937,369.33 in Q1 2023[22] - The net cash outflow from financing activities was CNY -213,794,177.42 in Q1 2024, compared to CNY -91,114,391.87 in Q1 2023, indicating a worsening of financing cash flow[23] - The ending cash and cash equivalents balance was ¥2,892,861,874.53, up from ¥120,244,955.68 in Q1 2023, reflecting a significant increase[31] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥21,333,719,480.20, a decrease of 0.83% from the end of the previous year[5] - The total liabilities decreased to ¥10,011,278,037.31 in Q1 2024 from ¥10,359,714,479.63 in Q1 2023, a reduction of approximately 3.4%[16] - The total equity attributable to shareholders increased to ¥11,150,230,331.46 in Q1 2024, compared to ¥11,005,533,096.56 in Q1 2023, marking a growth of 1.3%[16] - The company's total assets as of March 31, 2024, included cash and cash equivalents of CNY 2,960,242,910.11, a significant increase from CNY 552,139,166.87 at the end of 2023[24] Shareholder Information - The total number of common shareholders at the end of the reporting period was 18,642, with the largest shareholder, Aux Group Co., Ltd., holding 32.43% of shares[10] - The largest shareholder, Aux Group Co., Ltd., holds 457,719,653 shares, representing 32.43% of the total shares[10] - The company has no pledged, marked, or frozen shares among the top shareholders[10] Research and Development - Research and development expenses increased to ¥107,606,619.48 in Q1 2024, up from ¥79,357,579.39 in Q1 2023, reflecting a 35.6% rise[19] - Research and development expenses for Q1 2024 were ¥20,207,013.87, an increase from ¥18,672,699.63 in Q1 2023, indicating a focus on innovation[28] Operating Costs - Operating costs for Q1 2024 were ¥2,639,988,293.38, up 36.0% from ¥1,942,265,271.77 in Q1 2023[17] - The company reported a significant increase in sales expenses, which rose to ¥225,615,769.63 in Q1 2024 from ¥139,244,349.83 in Q1 2023, an increase of 62.0%[19] Financial Expenses - The company’s financial expenses increased significantly to ¥18,471,113.41 in Q1 2024 from ¥1,061,995.80 in Q1 2023, indicating a rise in financing costs[19] - The company's financial expenses surged to ¥9,218,239.90 in Q1 2024, compared to ¥2,459,209.29 in Q1 2023, primarily due to increased interest expenses[28] Inventory and Receivables - Accounts receivable increased to RMB 2.305 billion from RMB 2.209 billion year-on-year[14] - The company’s inventory increased to CNY 315,475,307.24 as of March 31, 2024, compared to CNY 271,584,679.16 at the end of 2023, reflecting a growth of approximately 16.1%[24] - The company’s other receivables rose to CNY 2,027,591,627.47 as of March 31, 2024, compared to CNY 1,908,042,131.16 at the end of 2023, indicating an increase of about 6.3%[24]